아프리카의 재발 뇌졸중 방지를위한 실로 스타 졸 (CLARITY-Africa)
Global estimates suggest that sub-Saharan Africa (SSA) now has the highest incidence, prevalence, and worst survival outcomes of stroke. With an estimated 1.4 million stroke survivors, outcomes of stroke in SSA are abysmal with 1-month case fatality at 30% and 3-year mortality rate of 84%. Stroke survivors in Africa are at an inordinately high (and worsening) risk of adverse outcomes including recurrent stroke and cardiac events over the medium- to longterm. Given the paucity of resources in the region, testing of therapies, which are potentially highly clinically efficacious and cost-effective, while developing local stroke research capacity and contributing to the global secondary stroke prevention evidence base, is urgently needed. Cilostazol, a phosphodiesterase 3 inhibitor, has shown promising efficacy and safety mainly among an Asian population by cutting risk of major adverse cardiovascular events including stroke, in half, when added to aspirin or clopidogrel (8% vs. 4%, HR 0.52, 95% CI 0.35-0.77), with no increased risk in bleeding or serious adverse events. Cilostazol's potentially strong efficacy, presumed pleiotropic effects, and relatively low cost, make it a highly appealing agent for use in stroke-prone, low-resource settings. Therefore, the overall objective of the CiLostAzol for pReventIon of recurrent sTroke in Africa (CLARITY-AFRICA) study is to deploy a hybrid study design to demonstrate the efficacy and safety of cilostazol twice daily in reducing MACE over 24 months vs. placebo among 1100 recent stroke patients encountered at 12 hospitals in Ghana. Secondly, CLARITY-AFRICA also seeks to develop an implementation strategy for routine integration and policy adoption of cilostazol for post-stroke cardiovascular risk reduction in an under-resourced system. Given its compelling efficacy among a predominantly Asian population, the National Institute of Neurological Disorders and Stroke (NINDS) is poised to fund a US-based clinical trial to assess the longer-term efficacy and safety of cilostazol in a study titled CiLostAzol for pReventIon of recurrent sTroke (CLARITY). The investigators are also aware that European and Australian funding agencies are considering stroke trials of cilostazol. A concurrently executed CLARITYAfrica trial would allow recruitment of a historically underrepresented and high-risk group (Africans), test a therapy that if efficacious could be affordable for broader regional implementation, permit transcontinental mentorship/collaborations, and leverage NINDS impending investment. CLARITY-AFRICA will assess implementation outcomes such as adoption, acceptability, cost, pertinent to uptake of cilostazol in Ghana to inform policy. Regardless of its outcome, findings from CLARITYAFRICA will contribute meaningful information from the African perspective to inform the formulation of guidelines for global adoption of cilostazol into routine care for secondary CVD risk prevention by international bodies such as the World Health Organization. This application will focus on the first 2 aims of CLARITY-AFRICA to conduct the trial and assess secondary outcomes.
연구 개요
상태
상태
정황
정황
개입 / 치료
개입 / 치료
연구 유형
연구 유형
등록 (추정된)
등록
단계
단계
- 3단계
연락처 및 위치
연구 연락처
연구 연락처
- 이름: Raelle Tagge, MPH
- 이메일: raelle.tagge@ncire.org
연구 연락처 백업
- 이름: Bruce Ovbiagele, M.D., MSc, MAS, MBA
- 전화번호: 415-750-2047
- 이메일: bruce.ovbiagele@va.gov
연구 장소
-
-
-
Kumasi, 가나
- Kwame Nkrumah University of Science & Technology
-
연락하다:
- Fred Sarfo, MD, PhD
- 전화번호: +233 32 206 0021
- 이메일: stephensarfo78@gmail.com
-
-
참여기준
자격 기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Above the age of 30 years; male or female (sex is a biological variable of interest)
- Ischemic stroke or high-risk TIA (ABCD2 score >= 6) diagnosis no greater than six months before enrollment. Ischemic strokes including lacunar, large vessel atherosclerotic, embolic stroke of undetermined source subtypes are eligible (Ischemic stroke or TIA should be confirmed by either with a cranial CT or MRI within 10 days of symptom onset)
- Aspirin or clopidogrel monotherapy
- Subjects with stroke may present with two or more of the following additional conditions: age ≥65 years, documented diabetes mellitus or previous treatment with oral hypoglycemic or insulin; documented hypertension >140/90mmHg or previous treatment with anti-hypertensive medications; Mild to moderate renal dysfunction (eGFR 60-30ml/min/1.73m2); Prior myocardial infarction
- Legally competent to sign informed consent or have a LARs who is able to provide consent for them
- In the opinion of the treating physician, patient is medically stable, capable of participating in a randomized trial, and willing and able to attend follow-up.
- Able to do labs at all study intervals (7 visits total)
Exclusion Criteria:
- Unable to provide a valid informed consent
- Contraindications to cilostazol (namely (i) hypersensitivity, (ii) active pathologic bleeding, e.g. bleeding peptic ulcer, intracranial bleeding due to reversible platelet aggregation, (iii) congestive cardiac failure.)
- Hemorrhagic stroke survivor within the last 2 years
- Use of an anticoagulant medication or indication for use of an anticoagulant (e.g. atrial fibrillation)
- On dual antiplatelet therapy (patients are eligible after completion of a course of dual antiplatelet therapy)
- Modified Rankin Scale 5
- Thrombocytopenia (platelet count <1000,000)
- Severe liver dysfunction (active hepatitis or hepatic insufficiency with Child-Pugh score B or C)
- Congestive heart failure, defined as NYHA Class III or above (marked limitation of physical activity)
- Nursing/pregnant mothers
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 방지
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 삼루타
팔의 수
무기와 개입
참가자 그룹 / 팔참가자 그룹 / 팔 |
개입 / 치료개입 / 치료 |
|---|---|
|
실험적: Cilostazol Experimental Arm
Patients allocated to the experimental arm will receive 100mg of cilostazol tablets taken twice daily. To mitigate side-effects in both treatment arms, all patients will begin one tablet daily and titrate to the full dose (one tablet twice daily) after 2 weeks. Participants will stay on the full dose of cilostazol for the remainder of the study. |
Patients allocated to the experimental arm will receive 100mg of cilostazol tablets taken twice daily. To mitigate side-effects in both treatment arms, all patients will begin one tablet daily and titrate to the full dose (one tablet twice daily) after 2 weeks. Participants will stay on the full dose of cilostazol for the remainder of the study. |
|
간섭 없음: Control Arm
Standard of post-stroke care |
연구는 무엇을 측정합니까?
주요 결과 측정
주요 결과 측정
결과 측정 |
기간 |
|---|---|
|
주요한 심혈관 사건을 가진 참가자의 비율
기간: 36 개월
|
36 개월
|
2차 결과 측정
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
주요 출혈 및 경미한 출혈 참가자의 비율
기간: 24 개월
|
24 개월
|
|
|
재발 성 뇌졸중 참가자의 비율 (허혈 또는 출혈성)
기간: 24 개월
|
24 개월
|
|
|
심혈관 사망 참가자의 비율
기간: 24 개월
|
24 개월
|
|
|
모든 원인 사망률을 가진 참가자의 비율
기간: 24 개월
|
24 개월
|
|
|
Neuro-QoL (Quality of Life)
기간: 24 months
|
12 monthly Neuro-QoL uses T-scores, which are standardized scores: Mean (average) = 50 Standard deviation = 10 Interpreting T-scores: Scores 0.5 - 1.0 SD worse than the mean = mild symptoms/impairment Scores 1.0 - 2.0 SD worse than the mean = moderate symptoms/impairment Scores 2.0 SD or more worse than the mean = severe symptoms/impairment For negative domains (e.g. anxiety, depression, fatigue): Higher = Worse We will compare mean Neuro-QoL scores between the two arms of the study at study completion as well as proportions with mild, moderate and severe impairment. |
24 months
|
|
Exploratory outcomes Montreal Cognitive Assessment
기간: 24 months
|
6 monthly. Comparison of Slopes of MOCA scores over 24 months. Range of scores on MOCA: 0 to 30. MOCA screening tool is used to detect mild cognitive impairment and early signs of dementia. It evaluates several cognitive domains, including: Memory Attention Language Visuospatial skills Executive function Orientation A score of 26 or above is considered normal. Scores below 26 may suggest cognitive impairment, depending on education level and clinical context. |
24 months
|
|
Quality of Life (EQ-5D Questionnaire)
기간: 24 months
|
The EQ-5D is a health-related quality of life questionnaire with two parts: Descriptive system: Assesses 5 dimensions-mobility, self-care, usual activities, pain/discomfort, and anxiety/depression-each rated on 3 or 5 levels (from no problems to extreme problems). Visual Analog Scale (VAS): Rates overall health from 0 (worst) to 100 (best). Scoring: The 5-digit health state is converted into a summary index score (range: <0 to 1), with 1 = full health. The VAS reflects the person's self-rated health. We will compare scores between the two arms at study completion. |
24 months
|
|
Modified Rankin Score
기간: 24 months
|
The Modified Rankin Scale (mRS) measures the degree of disability or dependence in daily activities after a stroke or other neurological injury. Scoring: 0 - No symptoms
|
24 months
|
공동 작업자 및 조사자
스폰서
스폰서
연구 기록 날짜
연구 주요 날짜
연구 시작 (추정된)
연구 시작
기본 완료 (추정된)
기본 완료
연구 완료 (추정된)
연구 완료
연구 등록 날짜
최초 제출
최초 제출
QC 기준을 충족하는 최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
처음 게시됨
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
마지막 업데이트 게시됨
QC 기준을 충족하는 마지막 업데이트 제출
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
기타 연구 ID 번호
- 24-41599
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
IPD 계획 설명
Individual participant level data will be aggregated and maintained as de-identified to protect PHI
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
미국에서 제조되어 미국에서 수출되는 제품
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .